233 related articles for article (PubMed ID: 21135090)
1. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.
Chaix A; Lopez S; Voisset E; Gros L; Dubreuil P; De Sepulveda P
J Biol Chem; 2011 Feb; 286(8):5956-66. PubMed ID: 21135090
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
4. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
[TBL] [Abstract][Full Text] [Related]
5. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.
Tanaka A; Konno M; Muto S; Kambe N; Morii E; Nakahata T; Itai A; Matsuda H
Blood; 2005 Mar; 105(6):2324-31. PubMed ID: 15561889
[TBL] [Abstract][Full Text] [Related]
6. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G; Metcalfe DD; Olivera A
Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
8. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
[TBL] [Abstract][Full Text] [Related]
9. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.
Yang Y; Létard S; Borge L; Chaix A; Hanssens K; Lopez S; Vita M; Finetti P; Birnbaum D; Bertucci F; Gomez S; de Sepulveda P; Dubreuil P
Blood; 2010 Aug; 116(7):1114-23. PubMed ID: 20484085
[TBL] [Abstract][Full Text] [Related]
10. Mast cell homeostasis and the JAK-STAT pathway.
Morales JK; Falanga YT; Depcrynski A; Fernando J; Ryan JJ
Genes Immun; 2010 Dec; 11(8):599-608. PubMed ID: 20535135
[TBL] [Abstract][Full Text] [Related]
11. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
12. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
Bibi S; Arslanhan MD; Langenfeld F; Jeanningros S; Cerny-Reiterer S; Hadzijusufovic E; Tchertanov L; Moriggl R; Valent P; Arock M
Haematologica; 2014 Mar; 99(3):417-29. PubMed ID: 24598853
[TBL] [Abstract][Full Text] [Related]
13. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
14. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
15. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal.
Voisset E; Lopez S; Dubreuil P; De Sepulveda P
Blood; 2007 Oct; 110(7):2593-9. PubMed ID: 17595334
[TBL] [Abstract][Full Text] [Related]
17. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.
Sundström M; Vliagoftis H; Karlberg P; Butterfield JH; Nilsson K; Metcalfe DD; Nilsson G
Immunology; 2003 Jan; 108(1):89-97. PubMed ID: 12519307
[TBL] [Abstract][Full Text] [Related]
18. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
19. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
20. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.
Fumo G; Akin C; Metcalfe DD; Neckers L
Blood; 2004 Feb; 103(3):1078-84. PubMed ID: 14551138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
